SAN DIEGO--(BUSINESS WIRE)-- Memgen, LLC announces the following abstract on ISF35, the Company’s lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.
An oral presentation (Abstract 168), entitled Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL) is scheduled for December 11th at 5:45 pm PST in Elizabeth Ballroom DE at the Manchester Grand Hyatt San Diego.
Dr. Januario Castro from Moores Cancer Center, University of California San Diego (UCSD), will provide updated results of a clinical trial evaluating the safety and efficacy of ISF35 in combination with chemotherapy in patients with fludarabine-refractory and/or 17p-deleted CLL. Patients with 17p-deleted CLL typically have loss of functional p53, a tumor suppressor, rendering their leukemia refractory to chemotherapeutic agents. Patients in this study received their own tumor cells modified to express ISF35. Following ISF35 cell therapy, patients received monthly courses of FCR, a standard chemotherapy regimen.
The study investigators, including Dr. Castro and Dr. Thomas Kipps from UCSD, Dr. Javier Pinilla-Ibarz from Moffitt Cancer Center, and Dr. Lee Schwartzberg from The West Clinic, concluded that the combination of ISF35 cell therapy plus FCR appears to be well-tolerated and highly effective in the CLL patients examined, with a complete response rate higher than those reported in the literature. ISF35 plus chemoimmunotherapy could thus offer an effective treatment option for CLL patients whose cancer would otherwise be resistant to standard forms of therapy.
Financial support for the study presented was provided in part by The Leukemia & Lymphoma Society Therapy Acceleration Program, a strategic initiative to speed the development of therapies that have the potential to change the standard of care for patients with blood cancers, especially in areas of high unmet medical need.
Memgen is a clinical-stage biotechnology company developing immunotherapies to improve survival and quality of life of patients with cancer, autoimmune conditions and infectious diseases. Memgen’s patent-protected, re-engineered molecules, which are based on the tumor necrosis factor (TNF) superfamily of molecules, target specific receptors expressed on disease cells such as tumors, eliminating the disease cells. Memgen’s technology is designed to overcome resistance of disease cells to chemotherapy.
Memgen’s lead product, ISF35, is an immunotherapy in clinical development for CLL, lymphomas, and solid tumors. More information about Memgen, which has offices in San Diego, CA, is available at www.memgenbio.com.
Mike McCloskey, 858-366-4309
Senior Project Manager
KEYWORDS: United Kingdom United States Europe North America California Germany
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Oncology Research Science